Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 21;10(1):75.
doi: 10.1038/s41523-024-00683-x.

Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502

Daniel G Stover #  1   2 , Roberto Salgado #  3   4 , Oleksander Savenkov  5 , Karla Ballman  5 , Erica L Mayer  6 , Mark Jesus M Magbanua  7 , Sherene Loi  4 , Mark Vater  8 , Kristyn Glover  8 , Mark Watson  9 , Yujia Wen  10 , W Fraser Symmans  11 , Charles Perou  12 , Lisa A Carey  12 , Ann H Partridge  6 , Hope S Rugo  7
Affiliations

Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502

Daniel G Stover et al. NPJ Breast Cancer. .

Abstract

Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free survival in randomized phase III trial CALGB 40502. sTILs were associated with progression-free and overall survival in chemotherapy-treated MBC when controlling for treatment arm; however, this effect did not remain significant after additional adjustment for hormone receptor status. CALGB is now part of the Alliance for Clinical Trials in Oncology. Trial Registration: ClinicalTrials.gov: NCT00785291.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflicts of interest related to the current analyses. S.L. serves as a member of the Editorial Board of npj Breast Cancer.

Figures

Fig. 1
Fig. 1. Study design and descriptive analyses of stromal TILs in CALGB 40502.
A CONSORT diagram. B Distribution of stromal TILs across all evaluable slides (n = 582). C Stromal TILs in combined primary samples (primary breast or lymph node) versus combined recurrent/metastatic (locoregional recurrence or distant metastatic sites). D Stromal TILs in primary breast versus primary lymph node versus locoregional recurrence versus distant metastatic sites. E Stromal TILs in distant metastatic sites. For C–E, box indicates 25th–75th percentile with median as center line and whiskers indicates 95th percentile above/below median. Mean value indicated below each variable. F Stromal TILs in paired primary breast cancer:metastasis or locoregional recurrence (LRR) within individual patients.
See this image and copyright information in PMC

References

    1. Salgado, R., Loi, S., Denkert, C. International Immuno-Oncology Biomarker Working Group on Breast Cancer. (2023). www.tilsinbreastcancer.org.
    1. Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol.25, 1536–1543 (2014). - PubMed
    1. Savas, P. et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat. Rev. Clin. Oncol.13, 228–241 (2016). - PubMed
    1. Mao, Y. et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One9, e115103 (2014). - PMC - PubMed
    1. Salgado, R. et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial. JAMA Oncol.1, 448–454 (2015). - PMC - PubMed

Associated data